Project Grant F31CA306130
Award Date 1/16/26
Completion Date Not listed
Dollars Obligated $50K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
- This federal Project Grant award in the amount of $159,540.00 was provided by the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) to the University of North Carolina at Chapel Hill to conduct research aimed at characterizing and overcoming MHC-I-mediated immune evasion in triple-negative breast cancer. The key products and services to be delivered under this 2.5-year award include: 1) Functionally and molecularly characterizing MHC-I-low breast tumors to determine how MHC-I loss...
- The U.S. National Cancer Institute (NCI) awarded a $151,040 Project Grant under the Cancer Research Manpower program (CFDA 93.398) to the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, Massachusetts. The grant supports research to investigate the role of interferon gamma (IFNγ) in promoting metastasis and immune evasion of triple negative breast cancer (TNBC). Specifically, the project aims to 1) elucidate the role of IFNγ in immune evasion during TNBC dissemination and metastatic...
- This Project Grant award of $124,134 from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) supports research to investigate the mechanisms of pathogenesis and treatment response in immune checkpoint inhibitor-induced colitis. The research aims to define the role of specific T cell subsets recruited from circulation in promoting inflammation and mediating therapeutic response in this condition, which can occur in up to 40% of cancer patients receiving immune checkpoint...
- This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) to the University of Pittsburgh provides $165,486.00 to investigate how the intracellular protein MALT1 promotes immunosuppression in the tumor immune microenvironment of triple-negative breast cancer (TNBC). The award aims to analyze MALT1 regulation of the TNBC tumor immune microenvironment by characterizing MALT1 protease-dependent secretion of immunosuppressive cytokines from TNBC cells. This...
- This Project Grant award, totaling $102,984, was provided by the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) to support research conducted by The Trustees of Columbia University in the City of New York. The research aims to dissect the novel role of Focal Adhesion Kinase (FAK) in modulating immunity during metastatic reactivation and progression of cancer. The key objectives are to investigate how FAK suppresses the STING innate immunity pathway, thereby enabling immune...
- The National Cancer Institute (CFDA 93.398 Cancer Research Manpower) awarded a $147,486 Project Grant to the Sloan-Kettering Institute for Cancer Research to support a 3-year research training program in cellular immunology and mechanobiology. The program aims to examine how the mechanical properties of the tumor microenvironment influence metastatic site preference and immune system response. Key research activities include in vivo modeling, biophysical measurements, and single-cell analysis to...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $400,000 in funding to Promilead, LLC to activate the TFEB protein and enhance the efficacy of immunotherapy for triple negative breast cancer (TNBC). The key objectives are to: Determine how TFEB expression and activation in TNBC cells can favorably modulate tumor-associated macrophages to suppress tumor growth. Prior research has shown that TFEB has tumor suppressive roles in breast...
- This federal Project Grant award of $144,768 from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program) supports research into PIK3C2A as a potential immunotherapeutic target for triple-negative breast cancer (TNBC). The researchers at the Trustees of Indiana University, Indianapolis hypothesize that inhibiting the PIK3C2A protein can enhance tumor antigen presentation, thereby potentiating the anti-tumor effects of immune checkpoint blockade therapy for TNBC. The research...
- This $284,201.82 Project Grant from the National Cancer Institute, a division of the Department of Health and Human Services, will fund research into malignant cell engagement in immune circuits of human colorectal cancer. The Broad Institute, Inc. will utilize single cell RNA sequencing data from over 700,000 malignant, immune, and stromal cells from colorectal cancer patients to test the hypothesis that malignant cells expressing interferon-stimulated genes acutely promote anti-tumor immunity,...
- This $135,993 Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) supports research at Duke University to investigate the role of the ABL kinase-regulated HIF-1α-TAZ signaling pathway in promoting brain metastasis in triple-negative breast cancer (TNBC). The goal is to evaluate whether ABL-dependent activation of HIF-1 and TAZ leads to enhanced expression of unique transcriptional targets that promote brain metastasis in TNBC, and whether...